---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053832"
form_type: "8-K"
ticker: "SION"
cik: "0002036042"
company_name: "Sionna Therapeutics, Inc."
filed_at: "2026-08-06T11:12:37+00:00"
generated_at: "2026-08-06T11:15:14.018914+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sionna Therapeutics Q2 2026 net loss $29.9M; cash $268.3M; Phase 2a and Phase 1 trials on track for summer data

## Summary
- Net loss of $29.9M for Q2 2026, compared to $18.1M in Q2 2025.
- R&D expenses $21.9M (up from $15.4M) and G&A $10.6M (up from $6.5M) driven by pipeline advancement.
- Cash and equivalents $268.3M as of June 30, 2026, expected to fund operations into 2028.
- PreciSION CF Phase 2a trial of SION-719 as add-on to standard of care on track for topline data summer 2026.
- Phase 1 trial of SION-451 in dual combinations with SION-2222 and SION-109 also on track for topline data summer 2026.

## SEC filing metadata
- accession: 0001628280-26-053832
- form_type: 8-K
- ticker: SION
- cik: 0002036042
- company_name: Sionna Therapeutics, Inc.
- filed_at: 2026-08-06T11:12:37+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/0001628280-26-053832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/sion-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053832
- JSON: https://secwatch.observer/filing/0001628280-26-053832.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.